Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229568 | 0.75 | ALDH1A1 (0.40) | ALDH1A1MAPTHTTPOLBLMNA | |
| SCHEMBL12838344 | 0.75 | SLC6A4 (0.32) | LMNA | |
| SCHEMBL12658317 | 0.72 | LMNA (0.41) | LMNACYP2A6 | |
| SCHEMBL148110 | 0.72 | IDO1 (0.46) | LMNACYP2A6 | |
| SCHEMBL13226847 | 0.71 | CYP2A6 (0.48) | CYP2A6 | |
| SCHEMBL12069191 | 0.70 | CYP2A6 (0.52) | ALDH1A1MAPTHTTPOLBLMNA | |
| SCHEMBL257059 | 0.67 | DAO (0.37) | LMNA | |
| SCHEMBL20834871 | 0.66 | CYP2A6 (0.32) | ALDH1A1MAPTHTTPOLBCYP2A6 | |
| SCHEMBL10427176 | 0.65 | ALDH1A1 (0.80) | ALDH1A1MAPTHTTPOLBLMNA | |
| SCHEMBL7499745 | 0.65 | ACHE (0.37) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ALDH1A1 3466/4885MAPT 659/4885HTT 284/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ALDH1A1 3466/4885MAPT 659/4885HTT 284/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ALDH1A1 3466/4885MAPT 659/4885HTT 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.